Objective:To study the safety and initial efficacy of Iressa in patients with recurrent and metastatic head and neck squamous cell carcinomas( HNSCC ) pretreated with platinum - based chemotherapy. Methods : Patients with recurrent and metastatic HNSCC who had treatment failure with at least 2 lines of chemotherapy including platinum were given Iressa at a fixed dose of 250mg daily. Treatment was continued until the patient experienced unacceptable side effects or disease progression. Results : Fifteen patients were enrolled. Treatment was well tolerated, and only grades 1 to 2 adverse events were observed. None of the patients achieved partial or complete response. Median time - to - progression was 4 months, and median overall survival was 16 months. Conclusion : Iressa was well tolerated, but the response rate was poor in this heavily pretreated study population, and its use in HNSCC is not recommended outside the context of clinical trial.%目的:探讨Iressa治疗复发或转移性头颈鳞状细胞癌的疗效和安全性.方法:对接受过二线化疗方案(至少一个化疗方案包括铂类)失败的复发或转移性头颈鳞状细胞癌患者,给予Iressa每日250mg口服,持续到患者出现不可接受的不良反应或疾病进展.结果:15例患者入组,Iressa 250mg/日口服治疗能够很好耐受,只出现1级和2级不良反应,但全组无1例患者获得部分反应或全消,中位疾病进展时间为4个月,中位总生存时间为16个月.结论:Iressa能够很好耐受,但是该组患者有效率很低,它在头颈鳞状细胞癌的使用除临床研究外不推荐使用.
展开▼
